{"id":1538,"date":"2026-05-21T10:34:44","date_gmt":"2026-05-21T10:34:44","guid":{"rendered":"https:\/\/one-peptides.com\/?p=1538"},"modified":"2026-09-29T16:51:42","modified_gmt":"2026-09-29T16:51:42","slug":"ostarine-mk-2866-the-most-studied-sarm-in-history-and-the-state-of-the-clinical-research","status":"publish","type":"post","link":"https:\/\/one-peptides.com\/de\/ostarine-mk-2866-the-most-studied-sarm-in-history-and-the-state-of-the-clinical-research\/","title":{"rendered":"Ostarine (MK-2866) \u2014 the most studied SARM in history and the state of the clinical research"},"content":{"rendered":"
\n\tHome<\/a>\n<\/span>\u00bb<\/span>\n\tSARMs & modulators<\/a>\n<\/span>\u00bb<\/span>\n\tOstarine (MK-2866) \u2014 the most studied SARM in history and the state of the clinical research\n<\/span><\/div><\/div>\n

A patient with advanced lung cancer may lose a substantial amount of muscle mass over several months. Not because they are not eating \u2014 they eat as much as they can. They lose muscle because the tumor reprograms metabolism into a catabolic mode: it breaks down muscle protein faster than the body can rebuild it. This is cachexia \u2014 wasting that affects more than half of oncology patients and accounts for a significant share of cancer-related deaths. For decades there was no molecule that could halt that process without generating serious side effects. Ostarine \u2014 the first SARM to reach phase III research \u2014 became one of the most frequently analyzed compounds in this context.<\/span><\/p>\n

\u26a0\ufe0f Chemical reagent intended exclusively for laboratory research (Research Use Only).<\/strong> Ostarine in the One-Peptides catalog is not a medicinal product, dietary supplement or food product. It is not intended for administration to humans or animals outside a controlled experimental environment. This article is educational and reviews the published scientific literature \u2014 all effects described are outcomes reported in studies (animal models, in vitro work or clinical trials where stated), not promises regarding human use.<\/span><\/p><\/blockquote>\n\r\n

In brief.<\/strong> Ostarine (MK-2866, enobosarm) is a selective androgen receptor modulator with the broadest human-study base among SARMs. In one phase 2 study, participants were randomised to placebo or ostarine for 12 weeks<\/strong>, while the longest published clinical study lasted 16 weeks<\/strong>; this defines the present boundary of long-term safety knowledge. Despite being the best documented compound in its class, ostarine has not been approved as a medicine<\/strong> and is included on the WADA Prohibited List (category S1). Research reagent (RUO).<\/p><\/div>\r\n\n

What is ostarine (MK-2866)?<\/h2>\n

Ostarine (clinical name: enobosarm; research codes: MK-2866, GTx-024) is a non-steroidal selective androgen receptor modulator (SARM) developed by the US company GTx Inc. (now Oncternal Therapeutics), headquartered in Memphis, Tennessee.<\/span>
\nThe project began in the late 1990s, when the team of Prof. James T. Dalton was looking for a compound with the anabolic properties of testosterone \u2014 but without its androgenic effects on the prostate, skin, and liver. After screening hundreds of candidates, GTx-024 (Ostarine) emerged as the molecule with the most favorable anabolic\/androgenic ratio in preclinical models.<\/span>
\nWhat distinguishes Ostarine from other SARMs is not so much its mechanism \u2014 shared across the class \u2014 as the quantity and quality of the clinical data. Ostarine is the only SARM that has reached phase III clinical trials in humans. No other SARM has accumulated a comparable evidence base.<\/span>
\nMore on the SARM class context is available in the overview article: What SARMs are: mechanism, generations, and the state of the research<\/em><\/span>.<\/span><\/p>\n

How does ostarine work?<\/h2>\n

Ostarine acts on the androgen receptor (AR) \u2014 the same protein activated by testosterone. The difference lies in what happens after binding.<\/span>
\nWhen testosterone binds AR, the receptor changes shape and recruits a set of coactivators (helper proteins) that “switch on” anabolic genes in muscle and bone \u2014 but also androgenic genes in the prostate, sebaceous glands, and hair follicles. Effect: muscle grows, but the prostate swells, skin oils up, and the hairline recedes.<\/span>
\nOstarine, after binding AR, triggers a different conformational change of the receptor. That different conformation recruits a different set of coactivators \u2014 those mainly present in skeletal muscle and bone tissue, and absent or inactive in the prostate and skin.<\/span>
\nAnalogy: imagine a lock with two modes of opening. Testosterone turns the key a full 360\u00b0 \u2014 opening every compartment at once. Ostarine turns the same key 180\u00b0 \u2014 opening only selected compartments. Same lock, same key, but different way of using it.<\/span>
\nIn preclinical models (rats) Ostarine showed an anabolic\/androgenic ratio of about 10:1 \u2014 meaning its muscle activity was ten times stronger than its prostate activity. For comparison: testosterone has a 1:1 ratio.<\/span><\/p>\n

What did clinical trials of ostarine report?<\/h2>\n\n

Clinical studies assessed enobosarm in different populations and endpoints, and the longest published trial lasted 16 weeks.<\/p>\n\n

Phase I \u2014 pharmacokinetics and safety<\/span><\/h3>\n

The first human studies were conducted in healthy volunteers. This phase reported good tolerability of the compound, linear pharmacokinetics, oral bioavailability and a half-life on the order of one day.<\/span><\/p>\n

Phase II \u2014 Dalton et al. (2011): healthy elderly volunteers<\/span><\/h3>\n

A randomized, double-blind, placebo-controlled study published in the Journal of Cachexia, Sarcopenia and Muscle<\/em>. A group of healthy older adults (men and postmenopausal women) was randomized to placebo and active Ostarine arms for 12 weeks.<\/span>
\nResults:<\/span><\/p>\n